Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Riedmann, K; Bassermann, F; Jost, PJ.
[Kinase inhibitors in oncology : What is new?]
Internist (Berl). 2019; 60(5):540-544
Doi: 10.1007/s00108-019-0577-8
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Jost Philipp
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in a wide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - therapeutic use
- Carcinoma, Non-Small-Cell Lung - drug therapy
- Carcinoma, Non-Small-Cell Lung - pathology
- Humans -
- Leukemia, Myeloid - drug therapy
- Leukemia, Myeloid - pathology
- Medical Oncology - trends
- Molecular Targeted Therapy -
- Neoplasms - drug therapy
- Protein Kinase Inhibitors - adverse effects
- Protein Kinase Inhibitors - therapeutic use
- Protein-Tyrosine Kinases -
- Find related publications in this database (Keywords)
- Protein kinase inhibitors
- adverse effects
- Protein-tyrosine kinases
- Molecular targeted therapy
- Leukemia, myeloid
- Carcinoma, non-small-cell lung